Scientists around the world had been hard at work to find antivirals specific to SARS-CoV-2, the virus that causes COVID-19.
Several drugs — such as chloroquine, arbidol, and remdesivir, and various other drug combinations — have undergone clinical studies to test their efficacy and safety in combating the coronavirus.
Avifavir is an anti-influenza medication in Japan approved in 2014.
On May 30, 2020 (Saturday) Russia’s Ministry of Health approved Avifavir for emergency use to treat COVID-19, after “encouraging” results from clinical trials of the generic version (Favipiravir) in several countries, including China and Japan. It is Russia’s first COVID-19 drug.
Now, Russia has licensed the antiviral drug Avifavir against coronavirus. Russian health authorities have given a green light to a clinical trials.
Favipiravir works by blocking the ability of a virus to replicate inside a cell. Some doctors began trying Favipiravir to treat coronavirus patients early on, reasoning that its anti-viral properties would be applicable.
Read more on Gulf News